文献速递营养与食品安全传染病防控与疫情报告

基于沙门菌的口服疫苗控制动物产志贺毒素大肠杆菌肠道定植的研发

Development of a Salmonella-based oral vaccine to control intestinal colonization of Shiga-toxin-producing Escherichia coli (STEC) in animals.
PubMed 文献 · Vaccine · 2022-01-25

产志贺毒素大肠杆菌(STEC)是重要食源性病原体,牛是重要环境储库,控制其肠道定植对防控人兽共患病关键。本研究以鼠伤寒沙门菌减毒株(ΔaroA突变体)为疫苗平台,构建融合STEC肽段EspA36-192、Intimin653-935、Tir258-361和H7鞭毛蛋白352-374的嵌合抗原EITH7,在小鼠模型中评估口服免疫效果。三剂免疫方案诱导黏膜和体液免疫应答,保护小鼠抵抗STEC口服实验感染;单剂方案仅诱导粪便α-EITH7 IgA抗体而无血清抗体,小鼠仍能有效控制1010 STEC(O157:H7株)口服感染,提示黏膜免疫应答对控制STEC肠道定植必要且充分。

要点

  • ΔaroA-ST(EITH7)三剂口服免疫诱导黏膜和体液免疫,保护小鼠抵抗STEC口服感染。
  • 血清抗体可结合嵌合抗原EITH7并阻断EPEC三型分泌系统触发的肌动蛋白基座形成。
  • 单剂免疫仅诱导粪便α-EITH7 IgA而无血清抗体,小鼠仍有效控制1010 STEC口服感染。

核心结论

  • 减毒鼠伤寒沙门菌ΔaroA株递送嵌合抗原EITH7的口服疫苗在小鼠模型中可诱导保护性免疫应答。
  • 单剂免疫方案仅诱导粪便α-EITH7 IgA抗体即可有效控制1010 STEC口服实验感染,提示黏膜免疫应答必要且充分。

研究设计与样本

  • 以鼠伤寒沙门菌减毒株(ΔaroA突变体)为疫苗平台,构建融合STEC肽段EspA36-192、Intimin653-935、Tir258-361和H7鞭毛蛋白352-374的嵌合抗原EITH7,融合β-内酰胺酶信号序列(bla SS)驱动分泌至细菌周质空间。
  • 在小鼠模型中评估口服ΔaroA-ST(EITH7)三剂免疫方案和单剂免疫方案对STEC肠道定植的控制效果。

主要发现

  • 三剂口服免疫方案诱导黏膜和体液免疫应答,保护小鼠抵抗STEC口服实验感染。
  • 血清抗体可结合嵌合抗原EITH7,并阻断肠致病性大肠杆菌(EPEC)三型分泌系统(T3SS)触发的肌动蛋白基座形成。
  • 单剂口服免疫方案仅诱导粪便α-EITH7 IgA抗体,未检测到血清α-EITH7抗体,小鼠仍能有效控制1010 STEC(O157:H7株)口服实验感染。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Shiga-toxin-producing Escherichia coli (STEC) is an important food-borne pathogen that causes hemorrhagic colitis and hemolytic uremic syndrome (HUS) in humans. Since no vaccines are available and antibiotic treatment is not recommended because promotes the appearance of HUS symptoms, the control of STEC intestinal colonization in cows, which is an important environmental reservoir, is crucial to control this zoonosis. Here, we evaluated the adaptation of an attenuated strain of Salmonella enterica serovar Typhimurium (ΔaroA mutant) as a vaccine platform for preventing STEC intestinal colonization that was studied in a mouse model. A chimeric antigen formed by the combination of the STEC peptides EspA36-192, Intimin653-935, Tir 258-361, and H7 flagellin352-374 (EITH7) was constructed and fused to the β-lactamase signal sequence (bla SS) that drives the secretion of the chimeric antigen to the bacterial periplasmic space. Oral administration of ΔaroA-ST(EITH7) in a regime of three doses of immunization elicited both mucosal and humoral immune responses that protect mice against a STEC oral experimental infection. Remarkably, serum antibodies not only were able to bind the chimeric antigen EITH7 but also to block actin pedestal formation triggered by the type three secretion system (T3SS) in Enteropathogenic Escherichia coli (EPEC). Furthermore, a single-dose protocol was evaluated, and mice were orally immunized with ΔaroA-ST(EITH7). Interestingly, although with this protocol of immunization only fecal α-EITH7 IgA antibodies were induced and no α-EITH7 in sera were detected, mice were able to efficiently control an oral experimental infection with 1010 STEC (strain Escherichia coli O157:H7), suggesting that mucosal immune response was necessary and sufficient to control STEC intestinal colonization.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Iannino F, Uriza PJ, Duarte CM, et al. Development of a Salmonella-based oral vaccine to control intestinal colonization of Shiga-toxin-producing Escherichia coli (STEC) in animals. Vaccine. 2022. PMID: 35086742. doi:10.1016/j.vaccine.2022.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。